The company provides integrated solutions for next-generation antibody drug development to the global biomedical communities, collaborating with more than 70% of the top 50 pharmaceutical and biotechnology companies worldwide. Biocytogen has two core products, YH003 and YH001, being developed for pancreatic ductal adenocarcinoma, melanoma, hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other advanced solid tumors.